Berlin Cures Announces Changes to Board of Directors to Propel Development of BC 007

Berlin Cures Holding AG has appointed Craig T. Basson, Gerrard Terlouw, and Oliver von Stein to its Board of Directors. These changes aim to advance the development of BC 007, the company's lead drug candidate currently in Phase II trials for Long COVID.

Craig T. Basson brings over 25 years of experience in cardiovascular medicine. Gerrard Terlouw has two decades of corporate and business development expertise in the pharmaceutical industry. CEO Oliver von Stein adds his extensive management experience to the board.

The company emphasizes the importance of cardiovascular disease and Long COVID as strategic priorities. The new board members are expected to enhance the preparation for the Long COVID Phase II trial read-out and future development strategies.

Ulf Berg, Johannes Müller, and Georg Nederegger are stepping down from the board. Müller will continue as Chief Science Officer, contributing to the company's research efforts.

Berlin Cures uses innovative aptamer-based drugs targeting harmful autoantibodies in autoimmune diseases. In addition to Long COVID, BC 007 also addresses heart failure and other conditions.